These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20097359)

  • 1. Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease.
    Schiffmann R; Martin RA; Reimschisel T; Johnson K; Castaneda V; Lien YH; Pastores GM; Kampmann C; Ries M; Clarke JT
    J Pediatr; 2010 May; 156(5):832-7, 837.e1. PubMed ID: 20097359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
    Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
    Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.
    Ramaswami U; Wendt S; Pintos-Morell G; Parini R; Whybra C; Leon Leal JA; Santus F; Beck M
    Acta Paediatr; 2007 Jan; 96(1):122-7. PubMed ID: 17187618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
    Schiffmann R; Ries M; Blankenship D; Nicholls K; Mehta A; Clarke JT; Steiner RD; Beck M; Barshop BA; Rhead W; West M; Martin R; Amato D; Nair N; Huertas P
    Genet Med; 2013 Dec; 15(12):983-9. PubMed ID: 23680766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease: overall effects of agalsidase alfa treatment.
    Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
    Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
    Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
    Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
    Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
    PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
    Kampmann C; Linhart A; Devereux RB; Schiffmann R
    Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
    Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
    Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.